Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aldeyra Therapeutics

6.47
-0.1950-2.93%
Volume:44.62K
Turnover:292.33K
Market Cap:386.31M
PE:-6.89
High:6.69
Open:6.69
Low:6.44
Close:6.67
Loading ...

High Growth Tech Stocks To Watch In The US March 2025

Simply Wall St.
·
11 Mar

Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference

Business Wire
·
10 Mar

Aldeyra Therapeutics: Strategic Pipeline Advancements and Financial Stability Drive Buy Rating

TIPRANKS
·
07 Mar

Aldeyra Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Aldeyra Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
04 Mar

Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

Business Wire
·
04 Feb

High Growth Tech Stocks To Watch In December 2024

Simply Wall St.
·
21 Dec 2024

Analysts’ Top Healthcare Picks: Aldeyra Therapeutics (ALDX), Keros Therapeutics (KROS)

TIPRANKS
·
16 Dec 2024

Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?

Zacks
·
09 Dec 2024

Positive Outlook for Aldeyra Therapeutics: Buy Rating Backed by Promising Reproxalap Prospects and Strategic Partnership with AbbVie

TIPRANKS
·
09 Dec 2024

Oppenheimer pharmaceuticals analysts hold analyst/industry conference call

TIPRANKS
·
04 Dec 2024

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Business Wire
·
02 Dec 2024

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap

Zacks
·
19 Nov 2024

Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application

Dow Jones
·
19 Nov 2024

Aldeyra announces FDA acceptance of resubmitted reproxalap application

seekingalpha
·
19 Nov 2024